Peptide News Digest

#Lipopeptide

2 stories

Research · View digest

Jena Chemists Show Pandoraea Bacteria Trim the Lipid Tail Off a Cyclic Peptide to Switch It From Swarming Aid to Iron Scavenger

Researchers at the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI) and the University of Jena, with senior author Christian Hertweck, reported in Angewandte Chemie International Edition that Pandoraea bacteria, a group that includes opportunistic pathogens, make lipopeptide siderophores called pandorachelins. An enzyme called PdnM removes the fatty-acid tail from pandorachelin B, triggering a rearrangement that contracts its ring into pandorachelin A, a head-to-tail cyclic peptide. The tailed form works as a surfactant that helps the bacteria swarm, while the trimmed form binds iron more tightly but no longer promotes movement. The paper was published online on July 24, 2026 and described by phys.org on September 25; the authors suggested the findings could inform drug delivery, but no medical use has been tested.

Regulatory · View digest

Gilead Hepcludex (Bulevirtide-gmod) FDA Accelerated Approval (May 22): First and Only US Treatment for Chronic Hepatitis Delta Virus, 47-Amino-Acid Lipopeptide NTCP Entry Inhibitor

The FDA granted accelerated approval on May 22, 2026 to Gilead Sciences' Hepcludex (bulevirtide-gmod) 8.5 mg, the first and only approved US treatment for adults living with chronic hepatitis delta virus (HDV) infection. Bulevirtide — formerly known as Myrcludex B — is a 47-amino acid, N-terminally myristoylated lipopeptide derived from the pre-S1 domain of the HBV large envelope protein. The molecule binds to the sodium taurocholate cotransporting polypeptide (NTCP) — the entry receptor that HDV and HBV both use to enter hepatocytes — and blocks viral entry as a first-in-class entry inhibitor. The Phase 3 MYR301 trial documented a statistically significant combined virologic and biochemical response at week 48 versus delayed-treatment control, supporting the accelerated-approval threshold. Continued approval depends on confirmatory trial verification of clinical benefit. Bulevirtide has been EU-approved under conditional marketing authorization since 2020. Gilead shares closed Friday at $134.36, up roughly 3%.